4DMedical (ASX:4DX) secured a contract with the US Department of Defense to conduct a pilot program using its CT Ventilation-Perfusion technology, ahead of the US Food and Drug Administration's clearance of the technology, according to a Monday filing with the Australian bourse.
The technology, which provides a detailed view of lung ventilation and perfusion without radioactive isotopes, will be used to assess lung function and detect conditions like chronic obstructive pulmonary disease and chronic thromboembolic hypertension in 80 active-duty military personnel, the filing said.
Under the agreement, 4DMedical will provide a fixed number of scan analysis reports, helping with the early detection and management of lung conditions, particularly in service members exposed to hazardous environments during military operations.
Financial terms were not disclosed.
Shares of the company soared past 9% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。